Core Viewpoint - The China International Import Expo (CIIE) serves as a vital bridge for global trade resources and an important platform for deep integration of domestic and international industries, showcasing China's market vitality and promoting stable global trade development [1][3]. Group 1: CIIE's Role and Impact - Since its inception in 2018, CIIE has transformed exhibits into commodities and exhibitors into investors, highlighting its roles in international procurement, investment promotion, cultural exchange, and open cooperation [3]. - GSK has participated in CIIE for eight consecutive years, evolving from a witness to a participant and promoter of China's economic development [3]. - GSK's Vice President emphasized CIIE's high-quality platform advantage and its role as a significant showcase of China's reform, opening up, and high-quality development achievements [3]. Group 2: GSK's Commitment to China - GSK views China as a crucial strategic market and believes it has become a core growth engine and a significant source of global innovation [5]. - The rapid growth of China's innovative pharmaceutical sector has positioned the country as a key player in global pharmaceutical innovation, injecting new vitality into the industry [7]. - GSK's commitment to China includes establishing a global innovation center and aligning its product pipeline with China's health strategies [11]. Group 3: Innovation and Collaboration - CIIE provides a platform for GSK to showcase innovative products and solutions, facilitating deep communication with government and industry partners to accelerate the implementation of innovations in China [9]. - GSK plans to present around 20 innovative products at this year's CIIE, focusing on areas such as respiratory and immune diseases, infections, vaccines, and oncology [9]. - GSK is actively collaborating with local partners to enhance the accessibility of its products and to explore innovative healthcare models in China [12]. Group 4: Future Outlook - GSK anticipates that breakthroughs in biopharmaceuticals and artificial intelligence in China will have a profound impact on the global pharmaceutical industry [5]. - The company aims to deepen its engagement in high-quality industry discussions and expand its network to uncover more collaboration opportunities [11]. - GSK is committed to integrating global resources with local advantages to foster an open and win-win industrial ecosystem in China [13].
GSK中国总经理余慧明:创新合作,共拓中国健康未来